SCHEMBL5635202

SCHEMBL5635202

N#Cc1cc(-c2cccnc2)oc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.45
KDM4E B2RXH2 5/20 0.44
CYP2A6 P11509 5/20 0.44
CYP2D6 P10635 4/20 0.44
CYP2C9 P11712 4/20 0.44
CYP2C19 P33261 4/20 0.44
CYP3A4 P08684 4/20 0.44
ALDH1A1 P00352 4/20 0.44
GAA P10253 3/20 0.44
CYP2E1 P05181 3/20 0.44
CYP2B6 P20813 3/20 0.44
GLA P06280 2/20 0.44
MEN1 O00255 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
BRCA1 P38398 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789380 0.80 MEN1 (0.50) KDM4EALDH1A1GAAMEN1HSD17B10
SCHEMBL27854213 0.74 MAOA (0.40) KDM4EALDH1A1GAAMEN1HSD17B10
SCHEMBL6773157 0.72 CYP11B2 (0.56) CYP11B2KDM4ECYP2A6CYP3A4ALDH1A1
SCHEMBL6439562 0.72 CYP11B2 (0.56) CYP11B2KDM4ECYP2A6CYP3A4ALDH1A1
SCHEMBL26104293 0.71 MAOB (0.41) CYP11B2KDM4EALDH1A1GAAMEN1
SCHEMBL18342012 0.71 ALDH1A1 (0.40) CYP11B2KDM4EALDH1A1GAAGLA
SCHEMBL3512492 0.71 CYP2A6 (0.50) CYP11B2KDM4ECYP2A6CYP2D6CYP2C9
SCHEMBL21044401 0.71 AXL (0.51) CYP11B2KDM4ECYP2A6CYP2D6CYP2C9
SCHEMBL20240079 0.69 KDM4E (0.49) CYP11B2KDM4ECYP2A6CYP2D6CYP2C9
SCHEMBL13363883 0.69 CHRNB2 (0.48) CYP11B2KDM4ECYP2A6CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US disclosed
US-20070088031-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-04-19 US disclosed
EP-1689753-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-08-16 EP disclosed
WO-2005061516-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO disclosed
WO-2005061516-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088031-A1 Novel chemical compounds GSK3B, GSK3A, GSKIP CYP11B2 1262/4885KDM4E 1488/4885CYP2A6 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.